Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Positive Clinical Trial Results and FDA Pre-NDA Meeting
Summary
On December 4, 2025, Praxis Precision Medicines, Inc. announced the successful completion of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding ulixacaltamide. The Company also reported positive results from the EMBOLD study for relutrigine, showing significant seizure reduction and functional improvements in patients with developmental and epileptic encephalopathies (DEEs). Additionally, the RADIANT study results for vormatrigine in patients with focal onset seizures (FOS) or generalized epilepsy indicated a substantial reduction in seizures. The Company expects to complete its NDA submission for relutrigine in early 2026 and is on track to initiate pivotal studies for vormatrigine.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement